Nektar Therapeutics (NKTR) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $65.90
• Market Cap: $1.97B
• EPS: $-10.11
• 52-Week High: $75.67
• 52-Week Low: $6.48

Market Sentiment

Nektar Therapeutics currently has a Bullish sentiment score of 0.15.

About Nektar Therapeutics

Nektar Therapeutics is a San Francisco-based biopharmaceutical company dedicated to the discovery and development of innovative therapies for significant unmet medical needs across diverse disease areas, including cancer, autoimmune disorders, and chronic pain. The company boasts a robust clinical pipeline and utilizes proprietary drug development technologies designed to improve both the efficacy and safety profiles of its therapeutics. With additional operational facilities in Huntsville, A...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Nektar Therapeutics and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does NKTR pay dividends?

Nektar Therapeutics (NKTR) does not currently pay a regular dividend.

What is NKTR's market cap?

Nektar Therapeutics (NKTR) has a market capitalization of $1.97B with a current stock price of $65.90.